These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3192381)

  • 1. Preclinical antitumor activity of batracylin (NSC 320846).
    Plowman J; Paull KD; Atassi G; Harrison SD; Dykes DJ; Kabbe HJ; Narayanan VL; Yoder OC
    Invest New Drugs; 1988 Sep; 6(3):147-53. PubMed ID: 3192381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
    Atassi G; Dumont P; Kabbe HJ; Yoder O
    Drugs Exp Clin Res; 1988; 14(9):571-4. PubMed ID: 3229319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of batracylin (NSC-320846) against solid tumors of mice.
    Mucci-LoRusso P; Polin L; Bissery MC; Valeriote F; Plowman J; Luk GD; Corbett TH
    Invest New Drugs; 1989 Nov; 7(4):295-306. PubMed ID: 2557298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.
    Plowman J; Narayanan VL; Dykes D; Szarvasi E; Briet P; Yoder OC; Paull KD
    Cancer Treat Rep; 1986 May; 70(5):631-5. PubMed ID: 3708611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat.
    Ames MM; Mathiesen DA; Reid JM
    Invest New Drugs; 1991 Aug; 9(3):219-25. PubMed ID: 1783521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of novel ailanthone derivatives in vitro and in vivo.
    Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T
    Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
    Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
    Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.
    Narita T; Yaguchi S; Komatsu T; Takase M; Hoshino A; Inaba M; Tsukagoshi S
    Cancer Chemother Pharmacol; 1990; 26(3):193-7. PubMed ID: 2357766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia].
    Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):201-9. PubMed ID: 1899547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
    Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
    Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
    Baguley BC; Grimwade CD; Kernohan AR
    Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1337-41. PubMed ID: 3841068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26.
    Chiuten DF; Muggia FM; Johnson RK
    Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512
    [No Abstract]   [Full Text] [Related]  

  • 16. Cause of variability in activity of samples of CCNU against P388 leukemia in vivo.
    Montgomery JA
    Cancer Treat Rep; 1980; 64(8-9):987-91. PubMed ID: 7448833
    [No Abstract]   [Full Text] [Related]  

  • 17. Stability of the in vivo P388 leukemia model in evaluation of antitumor activity of natural products.
    Marsh JC; Shoemaker RH; Suffness M
    Cancer Treat Rep; 1985 Jun; 69(6):683-5. PubMed ID: 4016772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).
    Roberts BJ; Hamelehle KL; Sebolt JS; Leopold WR
    Cancer Chemother Pharmacol; 1986; 16(2):95-101. PubMed ID: 3081269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.
    Bissery MC; Nguyen CH; Bisagni E; Vrignaud P; Lavelle F
    Invest New Drugs; 1993 Nov; 11(4):263-77. PubMed ID: 8157469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.